The states alleged Cephalon “made misrepresentations” to the U.S. Patent and Trademark Office, which “damaged the states and eligible consumers,” according to the settlement. However, Cephalon denied the allegations.
The settlement allocates $35 million for consumers who purchased Provigil.
In May 2015, Cephalon reached a $1.2 billion settlement with the Federal Trade Commission over issues with the same drug. The settlement resolved an antitrust lawsuit regarding Cephalon illegally blocking generic competition with Provigil.
Pennsylvania U.S. District Judge Mitchell Goldberg will review the settlement. Mr. Goldberg has overseen Cephalon’s other litigation involving Provigil.
More articles about supply chain:
CVS scraps coverage of 2 brand-name biotech drugs for biosimilars
Drug company drives $48k brain-eating amoeba treatment to SC hospital
Transforming data into insights that drive better outcomes
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
